KIDCOV Study to Track Kidney Injury Over One Year in Adults With and Without COVID-19 Infection

What this Trial Is About

This research aims to understand the impact of mild or sub-clinical COVID-19 infection in adults on kidney injury over a 12-month period. It addresses a gap in knowledge about kidney damage in outpatients with COVID-19 by studying both COVID-19 positive and negative individuals across diverse racial and ethnic backgrounds from California, Michigan, and Illinois. The goal is to gather data that can help guide prevention and treatment strategies for COVID-19 related kidney injury. Participants will be grouped into COVID-19 positive and negative cohorts. They will receive mailed urine collection kits at 2, 6, and 12 months after their COVID-19 PCR test to provide samples for biomarker analysis. No in-person visits are required, and the main focus is on measuring the urine-based KIT Score and other markers like NGAL and KIM-1 to track kidney injury over time. Throughout the study, participants will complete questionnaires and send urine samples by mail. Researchers will analyze these samples for biomarkers indicating kidney injury and compare results between the groups. The primary measurement is the continuous KIT Score after one year. This remote participation allows monitoring without leaving home, supporting safety and convenience over the study duration.

KIDney Injury in Times of COVID-19 (KIDCOV)